Responsible Side Effects Management in Oncology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

267 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-01

Study Completion Date

2017-09-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of pharmacovigilance in oncology. Monitoring and management of AEs during antineoplastic treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Monitoring and management of AE's during antineoplastic treatment. Comparison of AE's reported by patient with the ones recognised by the oncologist, and vice versa, during antineoplastic treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pharmacovigilance Oncology Antineoplastic Treatment

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pharmacovigilance in oncology antineoplastic treatment adverse events

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

all cancer patients receiving systemic antineoplastic treatment, ECOG 0-2

Exclusion Criteria

age \<18, \>75; other active and severe comorbidities; no solid cancer; IUC patients

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Robert Šeparović

PhD MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UHC Sestre milorsdnice

Zagreb, Croatia, Europe, Croatia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Croatia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2312201522122016

Identifier Type: -

Identifier Source: org_study_id